S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

A. Alizadeh, M. Eisen, and R. E. Davis, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, pp.503-514, 2000.

G. Wright, B. Tan, A. Rosenwald, E. H. Hurt, A. Wiestner et al., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proc Natl Acad Sci, vol.100, pp.9991-9997, 2003.

A. Rosenwald, G. Wright, and K. Leroy, Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma, J Exp Med, vol.198, pp.851-62, 2003.

B. Coiffier, E. Lepage, and J. Brière, CHOP chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, pp.235-277, 2002.

M. S. Czuczman, A. J. Grillo-lópez, and C. A. White, Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and Chop chemotherapy, J Clinic Oncol, vol.17, pp.268-76, 1999.

J. M. Vose, B. K. Link, and M. L. Grossbard, Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, J Clinic Oncol, vol.19, pp.389-97, 2001.

A. M. Staiger, M. Ziepert, and H. Horn, Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-hodgkin's lymphoma study group, J Clinic Oncol, vol.35, pp.2515-2541, 2017.

A. Younes, L. H. Sehn, and P. Johnson, Randomized phase III trial of Ibrutinib and Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma, J Clin Oncol, vol.37, pp.1285-95, 2019.

A. Davies, T. E. Cummin, and S. Barrans, Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial, Lancet Oncol, vol.20, pp.649-62, 2019.

F. Morschhauser, P. Feugier, and I. W. Flinn, Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI st, Blood, vol.132, pp.782-782, 2018.

J. G. Lohr, P. Stojanov, and M. S. Lawrence, Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing, Proceedings of the National Academy of Sciences of the United States of America, pp.3879-84, 2012.

R. D. Morin, K. Mungall, and E. Pleasance, Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood, vol.122, pp.1256-65, 2013.

L. Pasqualucci, V. Trifonov, and G. Fabbri, Analysis of the coding genome of diffuse large B-cell lymphoma, Nat Genet, vol.43, pp.830-837, 2011.

S. Dubois, P. Viailly, and S. Mareschal, Next generation sequencing in diffuse large B cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study, Clin Cancer Res, vol.22, pp.2919-2947, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01343064

C. G. Mullighan, Genome sequencing of lymphoid malignancies, Blood, vol.122, pp.3899-907, 2013.

J. Zhang and V. Grubor, Genetic heterogeneity of diffuse large B-cell lymphoma, Proc Natl Acad Sci, vol.110, pp.1398-403, 2013.

C. Steidl and R. D. Gascoyne, The molecular pathogenesis of primary mediastinal large B-cell lymphoma, Blood, vol.118, pp.2659-69, 2011.

S. Monti, B. Chapuy, and K. Takeyama, Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large b cell lymphoma, Cancer Cell, vol.22, pp.359-72, 2012.

G. Lenz, G. W. Wright, and N. Emre, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proceedings of the National Academy of Sciences of the United States of America, 105, pp.13520-13525, 2008.

B. Chapuy, C. Stewart, and A. J. Dunford, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat Med, vol.24, pp.679-90, 2018.

R. Schmitz, G. W. Wright, and D. W. Huang, Genetics and pathogenesis of diffuse large B-cell lymphoma, N Engl J Med, vol.378, pp.1396-407, 2018.

A. Reddy, J. Zhang, and N. S. Davis, Genetic and functional drivers of diffuse large b cell lymphoma, Cell, vol.171, pp.481-94, 2017.

M. Rotival, T. Zeller, and P. S. Wild, Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans, PLoS Genet, vol.7, p.1002367, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00711658

W. Liebermeister, Linear modes of gene expression determined by independent component analysis, Bioinformatics, vol.18, pp.51-60, 2002.

A. E. Teschendorff, M. Journée, P. A. Absil, R. Sepulchre, and C. Caldas, Elucidating the altered transcriptional programs in breast cancer using independent component analysis, PLoS Comput Biol, vol.3, p.161, 2007.

S. Dubois, S. Mareschal, and J. Picquenot, Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?, Oncotarget, vol.6, pp.16712-16736, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02327300

S. Dubois, P. Viailly, and E. Bohers, Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases, Clin Cancer Res, vol.23, pp.2232-2276, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01526582

S. Mareschal, P. Ruminy, and M. Alcantara, Application of the cghRA framework to the genomic characterization of diffuse large B-cell lymphoma, Bioinformatics, vol.33, pp.2977-85, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02329646

C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim et al., GIS-TIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol, vol.12, p.41, 2011.

C. Copie-bergman, P. Gaulard, and K. Leroy, Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study, J Clinic Oncol, vol.27, pp.5573-5582, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00424929

C. Copie-bergman, P. Cuillière-dartigues, and M. Baia, MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study, Blood, vol.126, pp.2466-74, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02331572

T. Molina, D. Canioni, and C. Copie-bergman, Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho, J Clin Oncol, vol.32, pp.3996-4003, 2014.

F. Jardin, M. H. Delfau-larue, and T. J. Molina, Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma, Leuk Lymph, vol.54, pp.1898-907, 2013.

N. A. Johnson, G. W. Slack, and K. J. Savage, Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clinic Oncol, vol.30, pp.3452-3461, 2012.

A. L. Shaffer, G. Wright, and L. Yang, A library of gene expression signatures to illuminate normal and pathological lymphoid biology, Immunol Rev, vol.210, pp.67-85, 2006.

A. Liberzon, A. Subramanian, R. Pinchback, H. Thorvaldsdottir, P. Tamayo et al., Molecular signatures database (MSigDB) 3.0, Bioinformatics, vol.27, pp.1739-1779, 2011.

A. Subramanian, P. Tamayo, and V. K. Mootha, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci, vol.102, pp.15545-50, 2005.

A. Liberzon, C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. P. Mesirov et al., The molecular signatures database hallmark gene set collection, Cell Syst, vol.1, pp.417-442, 2015.

G. Lenz, G. Wright, and S. S. Dave, Stromal gene signatures in large-b-cell lymphomas, N Engl J Med, vol.359, pp.2313-2336, 2008.

C. P. Hans, D. D. Weisenburger, and T. C. Greiner, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, pp.275-82, 2004.

P. Ruminy, P. Etancelin, and L. Couronné, The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma, Leukemia, vol.25, pp.681-689, 2011.

S. Mareschal, S. Dubois, and P. Viailly, Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes Chromosomes Cancer, vol.55, pp.251-67, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01237083

S. Dubois, P. Viailly, and S. Mareschal, Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study, Clin Cancer Res, vol.22, pp.2919-2947, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01343064

K. Karube, A. Enjuanes, and I. Dlouhy, Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets, Leukemia, vol.32, pp.675-84, 2018.

L. Pasqualucci and R. Dalla-favera, Genetics of diffuse large B-cell lymphoma, Blood, vol.131, pp.2307-2326, 2018.

B. Chen, M. S. Khodadoust, C. L. Liu, A. M. Newman, and A. A. Alizadeh, Profiling tumor infiltrating immune cells with CIBERSORT, Methods in molecular biology, pp.243-59, 2018.

F. Offner, O. Samoilova, and E. Osmanov, Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL, Blood, vol.126, pp.1893-901, 2015.

J. P. Leonard, K. Kolibaba, and J. A. Reeves, Randomized phase 2 open-label study of R-CHOP ± Bortezomib in patients (Pts) with untreated non-germinal center B-Cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the pyramid trial (NCT00931918), Blood, vol.126, 2015.

A. J. Novak, Y. W. Asmann, and M. J. Maurer, Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma, Blood Cancer J, vol.5, p.346, 2015.

A. M. Lesokhin, S. M. Ansell, and P. Armand, Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase IB study, J Clin Oncol, vol.34, pp.2698-704, 2016.